IDEXX Laboratories (IDXX) Investor Day 2026 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2026 summary
23 Aug, 2026Strategic vision and sector opportunity
Focus on innovation-driven growth in diagnostics, software, and AI to capture a $45B+ global testing opportunity in companion animal health.
Sector tailwinds include expanding, aging pet populations, increased medicalization, and strong pet-owner commitment across generations.
Diagnostics adoption is rising, with significant headroom for growth, especially in wellness blood work inclusion and international markets.
Breed mix is shifting toward higher-care breeds and longer lifespans, increasing annual spend and diagnostic needs.
Pet healthcare spending remains resilient across income segments and economic cycles, supporting durable long-term growth.
Innovation and product development
Multi-decade R&D investment exceeding $2.5B has created a full-stack innovation engine spanning biomarkers, instruments, software, and AI.
Recent launches include inVue Dx for cytology, IDEXX MultiCue Dx, and Catalyst proBNP for cardiac diagnostics, with Cancer Dx expanding to a multi-cancer panel at no extra cost.
Expansion of diagnostic categories such as oncology, cardiac, renal, and parasitology, with innovation contributing over 2% to recurring revenue growth.
Technology for Life approach enables continuous menu expansion and platform extensibility, driving recurring revenue.
Integrated software and AI solutions streamline workflows, enhance diagnostic accuracy, and support clinical decision-making.
Commercial execution and customer partnership
Commercial model emphasizes high customer proximity, partnership, education, and workflow integration to drive adoption of innovation.
Global expansion continues with investments in Spain, France, South Korea, and Canada, leveraging a proven playbook and deep customer partnerships.
Integrated solutions across point-of-care and reference labs increase customer loyalty, with 97%+ retention and high Net Promoter Scores.
Training, workflow simplification, and digital engagement solutions are key to supporting large-scale adoption in multi-site networks.
Customer feedback highlights the importance of standardization with flexibility, partnership-led growth, and the value of wellness plans in driving preventive care.
Latest events from IDEXX Laboratories
- Q2 revenue up 10% to $1.22B, EPS up 18%, and guidance raised on strong diagnostics growth.IDXX
Q2 2026 - AI-driven innovation and expanding diagnostics platforms are propelling strong growth and sector leadership.IDXX
Stifel Jaws & Paws Conference 2026 - CEO transition, board declassification, and all management proposals approved; 10% special meeting proposal rejected.IDXX
AGM 2026 - Q1 2026 revenue up 14%, EPS up 17%, and guidance raised on strong diagnostics growth.IDXX
Q1 2026 - 2025 saw robust growth, innovation, and governance changes, with key shareholder votes ahead.IDXX
Proxy filing - Key votes include director elections, auditor ratification, and board declassification.IDXX
Proxy filing - 2025 saw robust growth, innovation, and governance changes, with key shareholder votes ahead.IDXX
Proxy Filing - Double-digit revenue and EPS growth in 2025, with strong 2026 outlook and innovation momentum.IDXX
Q4 2025 - Strong 2024 growth and innovation drive robust 2025 outlook with margin and EPS expansion.IDXX
Q4 2024